Invests in
Sectors:
Locations:
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Skills
Education
- Uo
- Uo
- Uo
Lists including Inga
Investments
Work Experience
2020
Principal
2020
Investing in Healthtech, Life Sciences, TechBio in UK and Europe
2025
Director
2025
Led €31m Series C with ACT, Seroba, Charles River Labs in digital pathology AI company serving pharma and healthcare systems.
2023
Director
2023
Led $12m Series A: https://techcrunch.com/2024/03/20/healthcare-platform-anima-brings-salesforce-like-capabilities-to-clinics-raises-12m/
2023
Director
2023
Led £11.5m Series A - https://www.imubiosciences.com/news/imu-biosciences-secures-ps11-5-million-in-series-a-funding-to-revolutionise-immune-powered-precision-medicine
2023
Director
2023
Led €5m round: https://www.moltenventures.com/news/molten-ventures-leads-5m-round-in-oliva-to-expand-workplace-mental-health-support
2021
Director
2021
Led $17.5m Series A in 2021: https://aktiia.com/uk/london-vc-draper-esprit-leads-17-5m-series-a-in-hypertension-health-tech-startup-aktiia Most recent financing: https://aktiia.com/uk/aktiia-secures-chf-27-million-usd-30m-in-funding
2019 - 2020
Entrepreneur In Residence
2019 - 2020
Helping academic entrepreneurs commercialise products that they invent specialising in medical devices and healthtech. EIR in Biomedical Engineering at Duke, consistently rated in the top 3 BME departments in the US. Mentor in Residence at Office of Licensing and Ventures, with 17 start-ups in 2020.
2017 - 2019
Chief of Staff
2017 - 2019
**Inivata was acquired by Neogenomics for $390m in 2021** https://www.fiercebiotech.com/medtech/neogenomics-to-acquire-inivata-for-390m-after-success-lung-cancer-liquid-biopsy-collab Liquid biopsy molecular diagnostics company in oncology. Based in the US coordinating operations as Chief of Staff as the company gained regulatory approval and initial sales into the US healthcare system.
2017 - 2018
Principal
2017 - 2018
In January 2017, the venture investment teams at Imperial Innovations changed name to Touchstone Innovations, which was acquired by IP Group PLC, a FTSE250 company, a few months later. Identifying, building and investing in life science companies - therapeutics, medical devices, diagnostics and healthcare companies including digital health.
2014 - 2017
Non Executive Director
2015 - 2017
**Puridify, a bioprocessing company, was acquired by GE Healthcare in November 2017** https://www.touchstoneinnovations.com/news-room/2017/nov/28/portfolio-company-puridify-acquired-ge-healthcare/
Board Observer
2014 - 2015